Calgary Scientific forms partnership with Viatronix

Michael Bassett | | Health Imaging | Artificial Intelligence
Advanced visualization developer Calgary Scientific of Calgary, Alberta, has formed a strategic partnership with Viatronix of Stony Brook, N.Y.

According to the two companies, the partnership completes the Web enablement of Viatronix’s virtual colonoscopy applications. It involves the use of Calgary Scientific’s PureWeb platform to enable the Web-based use of advanced 3D applications such as Viatronix’s 3D product.

PureWeb will allow Viatronix’ users to utilize the V3D Colon application from anywhere, without having to download, configure or support any viewer of portal software from any client.

Michael Bassett,

Contributor

Related Content

FDA has approved over 1,000 clinical AI applications, with most aimed at radiology
Commercially available AI increases breast cancer detection by nearly 20%
Clinicians want AI to show its work
ACR Assess-AI national data registry tracks performance of clinical algorithms
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA
PHOTO GALLERY: Medical imaging technology at RSNA 2024

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.